GLP-1 Market
LLY $1145.46 ▼ -1.0% NVO $37.49 ▼ -1.1% PFE $28.29 ▼ -0.8% VKTX $31.28 ▼ -4.0% KLRA $10.77 ▼ -5.7% GPCR $30.27 ▼ -3.2% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ATB200

Company
Amicus Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for ATB200 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04808505

    A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

    Not yet reported Amicus Therapeutics 36 participants Est. completion 2027-07 14 sites Stand-alone
    Other conditions: Glycogen Storage Disease Type II Infantile Onset
    View official trial listing →
  • Recruiting NCT NCT06121011

    A Global Prospective Observational Registry of Patients With Pompe Disease

    Amicus Therapeutics 500 participants Est. completion 2034-12-20 41 sites
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT02675465

    First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

    Not yet reported, Not yet reported Amicus Therapeutics 29 participants Est. completion 2024-08-22 19 sites Stand-alone
    Other conditions: Pompe Disease
    View official trial listing →
  • Completed NCT NCT03729362

    A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

    Not yet reported Amicus Therapeutics 125 participants Est. completion 2021-01-15 73 sites Stand-alone
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Available NCT NCT03865836

    Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

    Amicus Therapeutics
    Other conditions: Pompe Disease
    View official trial listing →
  • Active, not recruiting NCT NCT03911505

    ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

    Not yet reported Amicus Therapeutics 21 participants Est. completion 2027-09 17 sites Stand-alone
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Completed NCT NCT04138277

    A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

    Not yet reported Amicus Therapeutics 119 participants Est. completion 2024-12-31 60 sites Stand-alone
    Other conditions: Pompe Disease (Late-onset)
    View official trial listing →
  • Available NCT NCT04327973

    Expanded Access for ATB200/AT2221 for the Treatment of IOPD

    Amicus Therapeutics 4 sites
    Other conditions: Pompe Disease Infantile-Onset
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ATB200, Cipaglucosidase Alfa

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.